Navigation Links
BGI to play a pivotal role in demonstrating the superior performance of RNA-Seq
Date:11/2/2011

November 2nd, 2011, Shenzhen, China - BGI, the world's largest genomic organization, today announced its participation and pivotal role in demonstrating the superior performance of RNA-Seq in predicting patient outcomes as part of the Sequencing Quality Control (SEQC) Project launched by the U.S. Food and Drug Administration (FDA). The SEQC, also known as MAQC-III, is the third phase of the MicroArray Quality Control (MAQC), aimed at assessing the technical performance of next-generation sequencing (NGS) platforms for RNA and DNA analyses.

Microarrays were expected to be a primary source for pharmacogenomic and toxicogenomic data, but its progress has been hampered due to concerns on the lack of reproducibility and accuracy of the derived data. Recently, more and more scientists have been gradually conducting pharmaceutical and medical studies by utilizing NGS technology for advancing personalized nutrition and medicine. In late 2008, FDA turned its attention to sequencing technology and issued a statement calling for volunteers to participate in SEQC.

With the rapid development of NGS technology, RNA-Seq, also known as "Whole Transcriptome Shotgun Sequencing," is being adopted by the biomedical research community and FDA-regulated industries because of its potential for higher sensitivity in detecting low expression genes and greater specificity in distinguishing isoforms, among other advantages. To demonstrate the utility of RNA-Seq technology in predicting patient outcomes, the FDA, BGI and the University Children's Hospital of Cologne have been conducting together a study of cancer prognosis to assess the performance of RNA-Seq and microarrays using 500 neuroblastoma samples from MAQC-II.

In this project, BGI performs sequence library construction and sequencing as well as bioinformatics analysis for the massive amount of data being produced. "With our rich experience in RNA-Seq research, we believe we can make a significant contribution to the development of RNA-Seq technology and help accelerate its translation to clinical application," said Dr. Zhiyu Peng, Vice President of Research & Cooperation Division at BGI.

Dr. Matthias Fischer from the University Children's Hospital of Cologne stated, "While we have built predictive models for neuroblastoma patients with microarray data, some of those still need to be improved. Compared with microarray, the resulting massive RNA-Seq sequence data could be utilized to better understand human transcriptomics and identify functional genetic variants associated with disease and drug risks."


'/>"/>

Contact: Jia Liu
liujia@genomics.cn
BGI Shenzhen
Source:Eurekalert

Related biology news :

1. CONRAD presents results of pivotal contraceptive study at Reproductive Health 2011
2. BGI to Play Pivotal Sampling, Next-Generation Sequencing and Bioinformatics Role in Earth Microbiome Project
3. Pivotal discoveries in age-related macular degeneration
4. Onconova announces FDA agreement of a SPA for a pivotal phase 3 trial of Estybon in MDS
5. Volcanoes played pivotal role in ancient ice age, mass extinction
6. SRNL demonstrating low-energy remediation with patented microbes
7. Seeking superior stem cells
8. Fat and healthy? York U study finds slim isnt always superior
9. AgriLife research: Multi-paddock grazing is superior to continuous grazing
10. Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management
11. First new C. difficile drug in a generation superior to existing treatments: Researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... Germany , February 28, 2017 News ... ... Amsterdam from 14 to 16 March, Materna ... destination, and show how seamless travel is a real benefit for ... has added biometrics to their passenger touch point solutions to take ...
(Date:2/22/2017)... 2017 With the biometrics market to ... four technologies that innovative and agile startups must ... in the changing competitive landscape: multifactor authentication (MFA), ... "Companies can no longer afford to ... Dimitrios Pavlakis , Industry Analyst at ABI ...
(Date:2/13/2017)... , Feb. 13, 2017  RSA Conference -- ... platform that is designed to enhance fraud detection ... release in the RSA Fraud & Risk Intelligence ... organizations to leverage additional insights from internal and ... to better protect their customers from targeted cybercrime ...
Breaking Biology News(10 mins):
(Date:3/24/2017)... and ROCKVILLE, Md. , March ... of Maxwell Biotech Venture Fund (MBVF), today announced positive ... added to the standard drug therapy regimen in patients ... small molecule drug discovered by scientists at Sequella, Inc. ... Institutes of Health. A total of ...
(Date:3/24/2017)... 2017 Agenus Inc. (NASDAQ: AGEN), an immuno-oncology ... cancer vaccines, today announced participation at the following conferences: ... Blair and Maidstone Life Sciences conference "Cancer Immunotherapy Conference" ... New York, NY . Agenus will participate ... 9:40 am: Robert B. Stein , M.D., Ph.D., ...
(Date:3/23/2017)... 23, 2017  SeraCare Life Sciences, Inc., a ... vitro diagnostics manufacturers and clinical laboratories, is ... multiplexed Inherited Cancer reference material ... next-generation sequencing (NGS). The Seraseqâ„¢ Inherited Cancer DNA ... from industry experts to validate the ability ...
(Date:3/23/2017)... YORK , March 23, 2017 ... ... of death, putting significant strain on health care systems, in ... cancer diagnoses rises, so too does the development of innovative ... minimum side effects. Among the many types of cancer treatments, ...
Breaking Biology Technology: